Characterization and Targeting of Leukemia Stem Cells in Human Hematologic Malignancies
The Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). In parallel, the lab also investigates normal human hematopoiesis and hematopoietic stem cells. Our lab uses experimental hematology methods, stem cell assays, genome editing, bioinformatics, and immunology to define and investigate drivers of leukemia stem cell behavior. As part of these studies, we have led the development and application of robust xenotransplantation assays for both normal and malignant human hematopoietic cells. The major areas of focus for the lab are the investigation of pre-leukemic/clonal hematopoiesis hematopoietic stem cells, heterogeneity in AML at the single cell and stem cell level, and development of cancer immunotherapies.
About Us
Ravi Majeti, Principal Investigator
A.B. Biochemical Sciences, Harvard University
M.D. University of California, San Francisco
Ph.D. University of California, San Francisco
Virginia and D.K. Ludwig Professor
Professor of Medicine, Division of Hematology
Director, Institute for Stem Cell Biology and Regenerative Medicine
Director, Stanford Ludwig Center for Cancer Stem Cell Research and Medicine
Lab Members
